Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program

International Journal of Environmental Research and Public Health
Dagmar F Hernandez-SuarezJorge Duconge

Abstract

Background: Variations in several clopidogrel-pharmacogenes have been linked to clopidogrel response variability and clinical outcomes. We aimed to determine the frequency distribution of major polymorphisms on CYP2C19, PON1, ABCB1 and P2RY12 pharmacogenes in Puerto Ricans. Methods: This was a cross-sectional, population-based study of 200 unrelated "Guthrie" cards specimens from newborns registered in the Puerto Rican newborn screening program (PRNSP) between 2004 and 2014. Taqman® SNP assay techniques were used for genotyping. Results: Minor allele frequencies (MAF) were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in Hardy⁻Weinberg equilibrium (HWE). Overall, there were no significant differences between MAFs of these variants in Puerto Ricans and the general population (n = 453) of the 1000 Genome project, except when comparisons to each individual parental group were performed (i.e., Africans, Europeans and East-Asians; p < 0.05). As expected, the prevalence of these markers in Puerto Ricans most resembled those in the 181 subjects fr...Continue Reading

References

Feb 3, 2004·The Journal of Clinical Investigation·Robert T Dorsam, Satya P Kunapuli
Sep 7, 2005·JAMA : the Journal of the American Medical Association·Marc S SabatineUNKNOWN Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
Oct 4, 2005·Expert Opinion on Pharmacotherapy·Udaya S TantryPaul A Gurbel
Jul 13, 2006·Proceedings of the National Academy of Sciences of the United States of America·Pierre SaviJean-Marc Herbert
May 20, 2008·International Journal of Cardiology·Peter StaritzBoris T Ivandic
Apr 21, 2009·Pharmacogenomics·Gualberto RuañoPedro J Santiago-Borrero
Sep 28, 2010·Lancet·Frank Pasqualone
Dec 21, 2010·Nature Medicine·Heleen J BoumanDirk Taubert
Mar 1, 2011·British Journal of Clinical Pharmacology·Terry K W MaBryan P Yan
May 24, 2013·Clinical Pharmacology and Therapeutics·S A ScottUNKNOWN Clinical Pharmacogenetics Implementation Consortium
Aug 29, 2013·British Journal of Clinical Pharmacology·Dietmar Trenk, Willibald Hochholzer
Sep 17, 2013·Journal of Pharmacogenomics & Pharmacoproteomics·Carmelo Orengo-MercadoJorge Duconge
Feb 11, 2014·Journal of Thrombosis and Thrombolysis·Julie H OestreichWendell S Akers
Oct 4, 2015·Nature·UNKNOWN 1000 Genomes Project ConsortiumGonçalo R Abecasis
Nov 26, 2016·Interventional Cardiology Clinics·Larisa H Cavallari, Aniwaa Owusu Obeng
Mar 2, 2017·Current Clinical Pharmacology·Jorge Duconge, Dagmar F Hernandez-Suarez
Jul 6, 2017·Therapeutic Advances in Cardiovascular Disease·Dagmar F Hernandez-SuarezJorge Duconge
Nov 15, 2017·Clinical Pharmacology and Therapeutics·Andrea GaedigkUNKNOWN PharmVar Steering Committee
Feb 7, 2018·Drug Metabolism and Personalized Therapy·Dagmar F Hernandez-SuarezJorge Duconge

❮ Previous
Next ❯

Citations

Sep 24, 2020·Journal of the American College of Clinical Pharmacy : JAACP·Idaliz Rodríguez-EscuderoJorge Duconge
Feb 4, 2022·Pharmacogenomics·Sasidharan Pillai V AswathyKanniappan Parthasarathy Arun

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping
PCR

Software Mentioned

ClinVar
Plavix

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.